ZIM
ALNY icon

Zacks Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Zacks Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
8,417
+560
+7% +$169K 0.02% 342
2026
Q1 		$2.6M Sell
7,857
-4,151
-35% -$1.41M 0.02% 318
2025
Q4 		$4.77M Buy
12,008
+104
+0.9% +$46K 0.04% 231
2025
Q3 		$5.43M Sell
11,904
-27
-0.2% -$11K 0.04% 212
2025
Q2 		$3.89M Sell
11,931
-10,331
-46% -$2.86M 0.03% 248
2025
Q1 		$6.01M Buy
+22,262
New +$5.72M 0.06% 203

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zacks Investment Management's ALNY Position: Q2 2026 in Review

Zacks Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 7.1% in Q2 2026, buying an estimated $169K and bringing the position to 8,417 shares worth $2.53M. The position accounts for 0.02% of the portfolio, ranked #342.

Zacks Investment Management first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.01M in Q1 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Zacks Investment Management held 8,417 shares of Alnylam Pharmaceuticals worth $2.53M as of Q2 2026.
  • Zacks Investment Management bought 560 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $169K.
  • Alnylam Pharmaceuticals made up 0.02% of Zacks Investment Management's portfolio in Q2 2026, its #342 holding.
  • Zacks Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Zacks Investment Management's Alnylam Pharmaceuticals position peaked at $6.01M in Q1 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.